Medivation Elects Kathryn Falberg to Board of Directors
Medivation (NASDAQ: MDVN) today announced that Kathryn E. Falberg has been elected to the Company's Board of Directors. Ms. Falberg will also serve as chair of the Audit Committee.
"We are delighted to welcome an experienced pharmaceutical executive of Kate's caliber to Medivation's board," said David Hung, M.D., president and chief executive officer of Medivation, Inc. "As prior chief financial officer at Amgen and current chief financial officer at Jazz Pharmaceuticals, Kate brings to our board critical and highly relevant experience successfully leading pharmaceutical companies through periods of rapid growth. Her financial acumen and strategic business and commercial insight will be invaluable additions to our board at a critical time of growth and transformation for Medivation."
"I am honored to join the Medivation Board of Directors at such an exciting time in the company's development," said Ms. Falberg. "I admire Medivation's success in identifying and developing novel therapies that treat diseases with limited therapeutic options and look forward to providing strategic guidance to help further grow its business."
Ms. Falberg currently serves as the executive vice president and chief financial officer of Jazz Pharmaceuticals plc. She also served as its senior vice president and chief financial officer from 2009 to 2012. From 1995 through 2001, Ms. Falberg was with Amgen, Inc., where she served as senior vice president Finance, Strategy and chief financial officer, and before that as vice president, controller and chief accounting officer, and vice president, treasurer. From 2001 through 2009, Ms. Falberg worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant. Ms. Falberg currently serves on the board, and is chair of the Audit Committee, of biopharmaceutical company Halozyme Therapeutics, Inc.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.